

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: InMed Pharmaceuticals Inc. (the "Issuer").

Trading Symbol: IN

Number of Outstanding Listed Securities: 68,232,862

Date: June 30, 2016

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

June 13, 2016 - the Company announced the addition of Dr. William J. Garner, M.D., to the Board of Directors. Dr. Garner is the founder of EGB Advisors PR LLC, a pharmaceutical commercialization boutique, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, M&A or IPO transactions. Dr. Garner has extensive director-level and executive management experience, including his current appointment as Chairman & Founder of Update Pharma and as a Director at IGXBio; previously serving as CEO of Invion Limited (ASX:IVX), a clinical-stage anti-inflammatory drug development company that resulted from the merger of a private company he founded; and as a co-founder and Director of Del Mar Pharmaceuticals (OCTQX:DMPID). Dr. Garner brings additional medical affairs experience from his tenure at Hoffmann LaRoche's oncology division. Prior to Roche, Dr. Garner was a healthcare merchant banker in New York City.

He has a Master of Public Health from Harvard and earned his M.D. at New York Medical College. Dr. Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of New York.

"I am excited about joining InMed's Board," stated Dr. Garner. "In my review of the drug development programs, which involve topical administration with an inherently reduced risk of systemic toxicity, it became clear that InMed has the potential to achieve important, value-driving milestones in diseases with high unmet medical needs. The ultra-orphan lead indication is a particularly attractive opportunity, in my opinion. Together with the Directors and Management of the Company, I believe my skill sets can augment InMed's efforts to optimize the development pathway and monetize its many assets."

InMed also announces it has accepted the resignation of Steve Tong as a Director of the Company, effective today. The Board wishes to thank Mr. Tong for his efforts on behalf of the Company.

June 16, 2016 - the Company announced the appointment of Mr. Eric A. Adams as CEO, President and as a member of the Board of Directors. Mr. Adams is a seasoned biopharmaceutical executive with over 25 years' experience in company and capital formation, global market development, mergers & acquisitions, licensing and corporate governance.

Mr. Adams states, "I'm excited to join InMed at this stage of its development. The assets developed to date by Dr. Sazzad Hossain, InMed's Chief Scientific Officer, and his research collaborators have significant potential for success. InMed's proprietary bioinformatics drug candidate database, its cutting edge cannabinoid biosynthesis program, and active drug development programs in epidermolysis bullosa, glaucoma and other promising disease targets provide an incredibly strong platform for the company's growth through both direct and licensed revenue models; there are short- and medium-term value driving milestones for InMed in all of these areas. We plan to monetize these assets and continue to fund development of important cannabinoid-based drugs for diseases with high unmet medical needs. I look forward to working with the management team and Board to build a successful, diversified drug development company that will tap into the vast potential of cannabinoid therapeutics and contribute to the understanding and commercialization of this important and largely undiscovered class of drugs."

Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTEC Canada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs. He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Chris Bogart will be stepping down as Interim CEO and resuming his role as SVP of Corporate Strategy and Investor Relations. Additionally, InMed announces it has accepted the resignation of Paul Brennan as a Director of the Company, effective today. The Board wishes to thank Mr. Brennan for his efforts.

2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

N/A

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

N/A

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

N/A

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

N/A

7. Describe the acquisition of new customers or loss of customers.

N/A

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A

9. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

N/A

10. Report on any labour disputes and resolutions of those disputes if applicable.

N/A

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

N/A

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A

13. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Date of issuance
Stock Options	1,000,000	Stock options incentives for New Director	June 10, 2016
Stock Options	2,000,000	Stock options incentives for New Officer	June 15, 2016
Common Shares	1,00,000	As per agreement dated June 15, 2016 between Eric Adams and InMed.	June 16, 2016

14. Provide details of any loans to or by Related Persons.
N/A

15. Provide details of any changes in directors, officers or committee members.

June 13, 2016:

William J. Garner was appointed to act as a Director
Stephen Tong resigned as a Director of the Company

June 15, 2016:

Eric Adams was appointed as a President, CEO and Director of the company
Chris Bogart stepped down as Interim CEO
Paul Brennan resigned as a Director of the Company

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.
N/A

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 30, 2016.

Eric A. Adams
Name of Director or Senior
Officer

"Eric A. Adams"
Signature

President and CEO
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer		YY/MM/D
InMed Pharmaceuticals Inc.	June 30, 2016	June 30, 2016
Issuer Address		
350-409 Granville Street		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC V6C1T2	(604)683.2506	(604)669.7207
Contact Name	Contact Position	Contact Telephone No.
Eric A. Adams	President and CEO	604.669.7207
Contact Email Address	Web Site Address	
eric@inmedpharma.com	www.inmedpharma.com	